Arrowhead Press Releases and News 
Arrowhead to Report Fiscal 2012 First Quarter Financial Results
PASADENA, Calif., February 2, 2012 — Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2012 first quarter ended December 31, 2011, on Thursday, February 9, 2012 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
read...Alnylam and Arrowhead Form Collaboration and Licensing Agreement
Cambridge, Mass. and Pasadena, Calif., January 5, 2012 –Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Arrowhead Research Corporation, (Nasdaq: ARWR) a nanomedicine company with development programs in RNAi and obesity, announced today that they have entered into a collaboration and joint licensing agreement.
read...Arrowhead Announces FDA Clearance to Initiate Adipotide™ Phase I Clinical Trial
PASADENA, Calif. — January 4, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application (IND) for its first obesity drug candidate, AdipotideTM, was accepted by the U.S. Food and Drug Administration allowing the initiation of a clinical trial to test the safety of the compound.
read...